Skip to main content
main-content

Chronic myeloid leukaemia

Chronic myeloid leukaemia

04-11-2016 | Chronic myeloid leukaemia | News | Article

EUTOS data give real-world overview of TKI use

European Treatment and Outcome Study findings suggest that real-world use of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia reflects that seen in clinical trials.

27-10-2016 | Chronic myeloid leukaemia | News | Article

MATE1 protein crucial for imatinib uptake

Cellular uptake of the tyrosine kinase inhibitor imatinib may be regulated by the multidrug and toxin extrusion protein 1, suggests research published in Blood Cancer Journal.

27-10-2016 | Chronic myeloid leukaemia | News | Article

CML patient motivation for TFR remission attempts highlighted

Researchers have reviewed the feasibility of, and motivation for, treatment-free remission in chronic myeloid leukaemia  patients with a deep molecular response to tyrosine kinase inhibitor therapy.

27-10-2016 | Chronic myeloid leukaemia | News | Article

IL-1 signalling key for leukaemic stem cell maintenance in CML

Preclinical research suggests that interleukin-1–mediated inflammatory signalling is crucial for the maintenance of chronic myeloid leukaemia stem cells persisting after treatment with tyrosine kinase inhibitors.

18-10-2016 | Chronic myeloid leukaemia | News | Article

Comorbidity predicts outcome in TKI-treated CML patients

Greater comorbidity burden at diagnosis is significantly associated with poor outcome in chronic myeloid leukaemia patients treated with tyrosine kinase inhibitors, a study shows.

18-10-2016 | Chronic myeloid leukaemia | News | Article

Long-term later-line bosutinib benefits CML patients

Bosutinib elicits durable responses in chronic phase–chronic myeloid leukaemia patients who have failed prior treatment with multiple tyrosine kinase inhibitors, shows an updated analysis of an ongoing phase I/II trial.

18-10-2016 | Chronic myeloid leukaemia | News | Article

ACAs characterised for blast phase–CML after TKI therapy

Researchers have characterised the pattern of additional chromosomal aberrations in patients with chronic myeloid leukaemia in the blast phase who have received tyrosine kinase inhibitor therapy.

16-09-2016 | Chronic myeloid leukaemia | News | Article

CML treatment-free remission linked to telomere length

Preliminary research has uncovered a possible correlation between duration of treatment-free remission in patients with chronic myeloid leukaemia and their relative telomere length.

16-09-2016 | Chronic myeloid leukaemia | News | Article

CML patient group calls for generic TKI use guidelines

A worldwide network of nonprofit organisations supporting patients with chronic myeloid leukaemia and their families has made key recommendations to address concerns regarding the use of generic forms of tyrosine kinase inhibitors.

16-09-2016 | Chronic myeloid leukaemia | News | Article

CML molecular monitoring standardisation for Latin America

Using secondary reference biological calibrators based on the World Health Organization primary standards may aid chronic myeloid leukaemia molecular monitoring in Latin America, research suggests.

12-08-2016 | Chronic myeloid leukaemia | News | Article

HRQoL improvements reported for bosutinib therapy in accelerated, blast phase CML

Patients with advanced phase chronic myeloid leukaemia may reap health-related quality of life benefits from second-line or later treatment with bosutinib, study findings suggest.

12-08-2016 | Chronic myeloid leukaemia | News | Article

Ultra-deep sequencing speeds TKI resistance mutation detection

Ultra-deep sequencing can detect the T315I tyrosine kinase inhibitor resistance mutation in patients with chronic myeloid leukaemia several months before conventional sequencing, study findings suggest.

12-08-2016 | Chronic myeloid leukaemia | News | Article

TKIs before, after transplantation feasible in advanced paediatric CML

Treatment with tyrosine kinase inhibitors prior to and after allogeneic haematopoietic stem cell transplantation may improve outcomes in children presenting with an advanced stage of chronic myeloid leukaemia, suggests a case series.

12-08-2016 | Chronic myeloid leukaemia | News | Article

ABCB1 mRNA overexpression may predict CML TKI outcomes

Monitoring early changes in ABCB1 messenger RNA expression could identify chronic phase chronic myeloid leukaemia patients likely to respond poorly to tyrosine kinase inhibitor treatment, shows a post hoc analysis of a phase II trial.

22-07-2016 | Chronic myeloid leukaemia | News | Article

Long-term dasatinib supported in CML

Dasatinib has durable efficacy and manageable toxicity in the long-term treatment of patients with chronic-phase chronic myeloid leukaemia that is resistant or intolerant to imatinib, shows final analysis of the CA180-034 trial.

22-07-2016 | Chronic myeloid leukaemia | News | Article

TKI therapy shows ‘excellent efficacy’ in Japanese CML population

A review of tyrosine kinase inhibitor therapy in Japanese patients with chronic myeloid leukaemia demonstrates high rates of treatment response and good outcomes but highlights the various issues associated with treatment discontinuation.

22-07-2016 | Chronic myeloid leukaemia | News | Article

‘Dramatic’ increase seen in CML life expectancy

Patients with chronic myeloid leukaemia can now expect to live almost as long as members of the general population, say researchers.

19-07-2016 | Chronic myeloid leukaemia | News | Article

CML patients sustain increased risk of vascular events

Patients treated for chronic myeloid leukaemia have a higher risk of arterial and venous vascular events than their counterparts in the general population, suggest the results of a Swedish cohort study.

14-06-2016 | Chronic myeloid leukaemia | News | Article

Salvage alloSCT remains option for progressing CML patients

Research demonstrates the continuing role of allogeneic stem cell transplantation as a salvage option for patients with chronic myeloid leukaemia who progress to accelerated phase or blast crisis after tyrosine kinase inhibitor failure.

14-06-2016 | Chronic myeloid leukaemia | News | Article

Maintenance TKI therapy ‘feasible’ for high-risk CML patients after allogeneic HSCT

Patients with high-risk chronic myeloid leukaemia who undergo allogeneic haematopoietic stem cell transplantation may benefit from continuing with tyrosine kinase inhibitor therapy, US clinicians believe.